Decheng Capital LLC — 13F Holdings & Portfolio
CIK 2010850 · latest 13F-HR filed 2026-11-13
Decheng Capital LLC manages $685.1M in 13F-reported U.S. long-equity assets across 11 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are CGON (65.93%), NUVB (21.22%), ACRS (3.10%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 0 new positions and exited 3; 0 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 99.9%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
BUILDING 2, SUITE 110
MENLO PARK, CA 94025
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CUI, XIANGMIN, NMN Control | MANAGING DIRECTOR since Nov 2011 | 75% or more | Individual |
| BAO, HONGBO, NMN | CHIEF COMPLIANCE OFFICER since Aug 2024 | Less than 5% | Individual |
| QIU, YUHENG, NMN | CHIEF FINANCIAL OFFICER since Aug 2024 | Less than 5% | Individual |
Ownership & leadership changes · 6 filings with changes since Jul 19, 2018
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- Listed againQIU, YUHENG, NMN · CHIEF FINANCIAL OFFICER · Less than 5%
- No longer listedQIU, YUHENG, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Oct 2023
- AddedBAO, HONGBO, NMN · CHIEF COMPLIANCE OFFICER · Less than 5%
- AddedQIU, YUHENG, NMN · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR; CHIEF COMPLIANCE OFFICER → MANAGING DIRECTOR
- No longer listedTSE, LAURA · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Nov 2021
- ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR → MANAGING DIRECTOR; CHIEF COMPLIANCE OFFICER
- AddedTSE, LAURA · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR/CHIEF COMPLIANCE OFFICER → MANAGING DIRECTOR
- ChangedCUI, XIANGMIN, NMN · title MEMBER → MANAGING DIRECTOR/CHIEF COMPLIANCE OFFICER
- ListedCUI, XIANGMIN, NMN · MEMBER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Trims
- Equillium Inc.-$7.0M -49.2%
- Upstream Bio Inc.-$4.5M -23.8%
- BeyondSpring Inc.-$4.3M -64.5%
- Arcus Biosciences, Inc-$3.3M -23.4%
- Lyell Immunopharma, Inc.-$2.9M -30.3%
Exited Positions
Show all 3 →Decheng Capital LLC Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 156944100 | $451.7M | 65.93% | 6,371,669 | SH |
| 2 | Nuvation Bio Inc. | NUVB | 67080N101 | $145.3M | 21.22% | 25,954,439 | SH |
| 3 | Aclaris Therapeutics, Inc. | ACRS | 00461U105 | $21.3M | 3.10% | 4,041,736 | SH |
| 4 | AARDVARK THERAPEUTICS INC | AARD | 002942100 | $20.6M | 3.01% | 3,917,299 | SH |
| 5 | Upstream Bio Inc. | UPB | 91678A107 | $14.4M | 2.10% | 2,724,868 | SH |
| 6 | Arcus Biosciences, Inc | RCUS | 03969F109 | $11.0M | 1.60% | 425,079 | SH |
| 7 | Equillium Inc. | EQ | 29446K106 | $7.2M | 1.05% | 4,447,308 | SH |
| 8 | Lyell Immunopharma, Inc. | LYEL | 55083R104 | $6.8M | 0.99% | 692,050 | SH |
| 9 | Zentalis Pharmaceuticals Inc. | ZNTL | 98943L107 | $3.7M | 0.54% | 1,323,327 | SH |
| 10 | BeyondSpring Inc. | BYSI | G10830100 | $2.4M | 0.34% | 3,065,702 | SH |
| 11 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 747324101 | $761.5K | 0.11% | 326,810 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $685.1M | 11 | 0001104659-26-127247 |
| 2026-06-30 | 2026-08-14 | $731.7M | 14 | 0001104659-26-096837 |
| 2026-03-31 | 2026-05-13 | $661.3M | 14 | 0001104659-26-060145 |
| 2025-12-31 | 2026-02-12 | $743.4M | 19 | 0001104659-26-014146 |
| 2025-09-30 | 2025-11-14 | $573.2M | 23 | 0001104659-25-112117 |
BUILDING 2, SUITE 110
MENLO PARK, CA 94025